- Home
- AUPH vs ECC Comparison
AUPH vs ECC Comparison
Compare AUPH & ECC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUPH
- ECC
- Stock Information
- Founded
- AUPH 1993
- ECC 2014
- Country
- AUPH Canada
- ECC United States
- Employees
- AUPH N/A
- ECC N/A
- Industry
- AUPH Biotechnology: Pharmaceutical Preparations
- ECC
- Sector
- AUPH Health Care
- ECC
- Exchange
- AUPH Nasdaq
- ECC NYSE
- Market Cap
- AUPH 1.1B
- ECC N/A
- IPO Year
- AUPH 1999
- ECC N/A
- Fundamental
- Price
- AUPH $8.86
- ECC $7.55
- Analyst Decision
- AUPH Strong Buy
- ECC Buy
- Analyst Count
- AUPH 2
- ECC 2
- Target Price
- AUPH $11.50
- ECC $9.25
- AVG Volume (30 Days)
- AUPH 2.0M
- ECC 1.2M
- Earning Date
- AUPH 07-31-2025
- ECC 08-05-2025
- Dividend Yield
- AUPH N/A
- ECC 24.62%
- EPS Growth
- AUPH N/A
- ECC N/A
- EPS
- AUPH 0.27
- ECC N/A
- Revenue
- AUPH $247,295,000.00
- ECC $191,298,536.00
- Revenue This Year
- AUPH $12.15
- ECC $26.00
- Revenue Next Year
- AUPH $18.31
- ECC $9.62
- P/E Ratio
- AUPH $33.08
- ECC N/A
- Revenue Growth
- AUPH 29.20
- ECC 29.29
- 52 Week Low
- AUPH $5.20
- ECC $6.54
- 52 Week High
- AUPH $10.67
- ECC $10.11
- Technical
- Relative Strength Index (RSI)
- AUPH 64.10
- ECC 40.88
- Support Level
- AUPH $7.36
- ECC $7.74
- Resistance Level
- AUPH $9.10
- ECC $7.83
- Average True Range (ATR)
- AUPH 0.44
- ECC 0.08
- MACD
- AUPH 0.10
- ECC 0.01
- Stochastic Oscillator
- AUPH 89.53
- ECC 17.50
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.